AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Agomelatine
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyritinol
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piracetam
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicergoline
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acamprosate
Study NCT02374567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Study NCT02314832 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adductor canal block
Description: ultrasound guided saphenous nerve block in the adductor canal
Study NCT02314832 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: femoral nerve block
Description: ultrasound guided femoral nerve block
Study NCT04300036 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: longan syrup
Description: Subjects will take 15 ml of longan syrup once a day for 3 months
Study NCT04300036 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo syrup
Description: Subjects will take 15 ml of placebo syrup once a day for 3 months
Study NCT01078649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 1143 (AT-406)
Description: Oral Debio 1143 (AT-406) will be administered in a dose escalation study to determine the maximally tolerated dose in humans. Patients will receive Debio 1143 (AT-406) on days 1-5, and 15-19 of a 28 day cycle, or days 1-5 of a 21 day cycle, repeated until progression or unacceptable toxicity occurs.
Study NCT02808910 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudged to eat less added salt and more other seasonings
Study NCT02808910 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudged to avoid foods high in salt content, and to choose foods low in salt content
Study NCT01940809 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT02808910 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudged to eat more vegetables
Study NCT02808910 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudged to eat smaller portions
Study NCT02808910 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudged to eat less calorie-dense food
Study NCT02448589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-119
Study NCT01940809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study NCT00192504 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Motavizumab
Description: Single dose of Motavizumab at a dose of 3 mg/kg administered intravenously (in the vein) on Day 0
Study NCT00192504 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Motavizumab
Description: Single dose of Motavizumab at a dose of 15 mg/kg administered intravenously (in the vein) on Day 0
Study NCT00192504 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Motavizumab
Description: Single dose of Motavizumab at a dose of 30 mg/kg administered intravenously (in the vein) on Day 0
Study NCT00192504 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo administered intravenously (in the vein) on Day 0
Study NCT01593800 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bio-25
Description: Bio-25 is an innovative formula containing 11 different strains of unique probiotic bacteria and over 25 billion active bacteria in each capsule. All participants will receive either Probiotics (Bio-25,will be provided by SupHerb) or placebo pills blindly for six months. One day prior to each visit, subjects will be asked to consume lactose, fructose and sorbitol free foods, in order to avoid high base line of hydrogen from the presence of unabsorbed carbohydrates. Subjects will also be asked not to smoke 24 hours prior to each visit.
Study NCT01068015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: behavior intervention and male circumcision
Description: MSM in intervention arm can receive circumcision service for free, POL intervention, intensive HIV counseling and intensive condom promotion.
Study NCT01068015 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: behavior intervention and male circumcision
Description: MSM in intervention arm can receive circumcision service for free, POL intervention, intensive HIV counseling and intensive condom promotion.
Study NCT04139967 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short course radiation therapy
Description: 25 Gray in 5 fractions over 5-7 days
Study NCT04789018 — intervention group
Intervention type: OTHER
Intervention: Educational Intervention
Description: Attend virtual genetics board
Study NCT04789018 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study NCT03693079 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wet cupping therapy
Description: CT was applied using plastic disposable vacuum cups on the back in the 5 areas of C7 cervical spine (DU14 acupoint), T2-4 lateral spine bilaterally (BL41-42 acupoint) and T6-8 lateral spine bilaterally (BL44-46). The cupping technique procedure was conducted in five phases:~1. Primary suction; cups are left attached to the skin for 5 minutes.~2. Area disinfection; areas are wiped with sterile gauze after disinfection with povidone iodine.~3. Scarification; Superficial incisions (20-30 gauge), 5 mm length and 1-2 mm depth, are made on the skin with a sterile, number 11 surgical blade.~4. Bloodletting and secondary suction; the cups which had been previously removed are placed again on the scarified areas Blood leaks from the capillary vessels of the skin and subcutaneous tissue and fills the cups, which are left in place for 15 minutes.~5. Removing and dressing; the cups full of blood are removed. The areas of application are wiped with sterile gauze and then a dressing is applied
Study NCT02297828 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boussignac CPAP
Description: Boussignac CPAP with a 50% FiO2 (adjusted in a piece adapted to the system) and a pressure of 5cmH2O (measured with a manometer) is applied immediately after extubation and mantained for two hours after extubation in the post anesthesia care unit (PACU).
Study NCT02297828 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Venturi face mask
Description: Venturi mask with a 50% FiO2 is used immediately after extubation and mantained for two hours in the post anesthesia care unit (PACU).
Study NCT02157142 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HLT Transcatheter Aortic Valve System
Description: Transcatheter aortic valve replacement with an HLT Transcatheter Aortic Valve System
Study NCT02417012 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: U-TURN
Description: Participants in this group will receive individual and group based interventions on obtaining and maintaining a healthy lifestyle, while having the pharmacological treatment regulated
Study NCT02417012 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard individual diabetes support
Study NCT02890979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Undergo cytology specimen collection procedure using a swallowable sponge cell sampling device
Study NCT02890979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02890979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02890979 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Swallowable Sponge Cell Sampling Device
Description: Undergo cytology specimen collection procedure using a swallowable sponge cell sampling device
Study NCT00265343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asenapine
Description: 5-10 mg sublingually twice daily for 26 weeks
Study NCT00265343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: 5-20 mg by mouth once daily for 26 weeks
Study NCT00573755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: given orally
Study NCT00573755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anastrozole
Description: given orally
Study NCT04789018 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Complete interview
Study NCT02020811 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sentinel
Study NCT04382066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plitidepsin 1.5 mg/day
Description: Plitidepsin 1.5 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.~All patients must receive the following prophylactic medications 20-30 minutes before the infusion of plitidepsin:~* Diphenhydramine hydrochloride 25 mg iv or equivalent.~* Ranitidine 50 mg iv or equivalent.~* Dexamethasone 8 mg iv.~* Ondansetron 8 mg i.v. 15 minutes infusion or equivalent.~* Ondansetron 4 mg p.o. administered every 12 hours until 48 hours after the last administration of plitidepsin.
Study NCT04382066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plitidepsin 2.0 mg/day
Description: Plitidepsin 2.0 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.~All patients must receive the following prophylactic medications 20-30 minutes before the infusion of plitidepsin:~* Diphenhydramine hydrochloride 25 mg iv or equivalent.~* Ranitidine 50 mg iv or equivalent.~* Dexamethasone 8 mg iv.~* Ondansetron 8 mg i.v. 15 minutes infusion or equivalent.~* Ondansetron 4 mg p.o. administered every 12 hours until 48 hours after the last administration of plitidepsin.
Study NCT04382066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plitidepsin 2.5 mg/day
Description: Plitidepsin 2.5 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.~All patients must receive the following prophylactic medications 20-30 minutes before the infusion of plitidepsin:~* Diphenhydramine hydrochloride 25 mg iv or equivalent.~* Ranitidine 50 mg iv or equivalent.~* Dexamethasone 8 mg iv.~* Ondansetron 8 mg i.v. 15 minutes infusion or equivalent.~* Ondansetron 4 mg p.o. administered every 12 hours until 48 hours after the last administration of plitidepsin.
Study NCT01979692 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: confocal laser microscopy CLM at trans thoracic needle biopsy TTNB
Study NCT01979692 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT guided trans thoracic needle biopsy
Study NCT01625364 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHARP program
Description: Staying Healthy-Asthma Responsible and Prepared is an academic and counseling asthma health education program for older school-age students with asthma and members of their social networks including their family caregivers.
Study NCT01625364 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Open Airways for Schools
Description: OAS is a non-academic asthma health education program for elementary students with asthma and their parents.
Study NCT00573755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: given orally
Study NCT00573755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exemestane
Description: given orally
Study NCT03908918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness app
Description: Mobile app-delivered mindfulness intervention delivered over 4 weeks.
Study NCT03908918 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mindfulness app
Description: Mobile app-delivered mindfulness intervention delivered over 4 weeks.
Study NCT01996956 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: volume expansion
Description: fluid loading of 10 ml/kg colloid or blood product
Study NCT01657734 — intervention group
Intervention type: OTHER
Intervention: MR imaging
Description: MR imaging
Study NCT00020878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Dosing will occur for a total of 6 months. 400 mg by mouth twice daily.
Study NCT00387725 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rLP2086
Description: Vaccine administered at 0, 1, and 6 months
Study NCT04279509 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Core Biopsy
Description: Performed up to a maximum of 3 time points - baseline upon study enrolment, at the completion of treatment, and upon disease progression.~Four to six tumour core samples will be obtained at each time point. At least two tumour cores will be sent fresh to Invitrocue Pte Ltd for generation of patient-derived organoids for drug-panel screening, at least 1-2 tumour cores at each time point will be stored in formalin and paraffin-embedded for immunohistochemistry analysis of biomarkers, while the remaining 1-2 tumour cores will be stored in liquid nitrogen for subsequent DNA, RNA and protein extraction for biomarker studies including gene expression and proteomics analyses.
Study NCT04279509 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Germline DNA at baseline for pharmacogenetics analysis. Serial plasma samples for circulating tumour cells and biomarkers, at baseline, prior to day 1 of each cycle while on treatment, at the end of treatment (either upon disease progression or upon completion of predetermined cycles of chemotherapy).
Study NCT02372539 — intervention group
Intervention type: OTHER
Intervention: Diabetes
Description: All patients enrolled in study will be given dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting. This will already be a part of their chemotherapy regimen and will not be prescribed by study investigators
Study NCT02372539 — intervention group
Intervention type: OTHER
Intervention: Control Group
Description: All patients enrolled in study will be given dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting. This will already be a part of their chemotherapy regimen and will not be prescribed by study investigators
Study NCT01226134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itopride,
Description: Itopride,50 mg capsules,thrice a day,for Four weeks
Study NCT00387725 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rLP2086
Description: Vaccine administered at 0, 1, and 6 months
Study NCT03873935 — intervention group
Intervention type: OTHER
Intervention: Evaluation of periodontal status
Description: Clinical examination
Study NCT01226134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsules,thrice a day for four weeks
Study NCT00411229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1,000 mg/m² twice daily. Film coated tablets of 500 mg, 150mg.
Study NCT00573755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: given orally
Study NCT00411229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: IV infusion, 130mg/m²
Study NCT00573755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: letrozole
Description: given orally
Study NCT00573755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: given orally
Study NCT00573755 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: given orally
Study NCT02271295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparine
Description: Enoxaparine 4000UI/day during 24 months
Study NCT00743418 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: GPS modem and RFID
Description: The participant will take the GPS kit with him/her everywhere during the whole day for a period of 4 weeks. The GPS tracking kit consists of a GPS receiver with a GSM modem, an RF transmitter contained in a wrist-watch and a monitoring unit located in the home that enables researchers to know whenever the tracked person leaves home. The waterproof RF transmitter will allow researchers to know whether or not research subjects leave home with the GPS device and if they are carrying the device or not at a given moment.
Study NCT03899909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3121 SAD
Description: GLPG3121 oral suspension, single ascending doses
Study NCT01442415 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle modification
Description: Weekly lifestyle modification sessions including dietary counseling and physical activity
Study NCT00405756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide: Double-blind Induction
Description: Double-blind Induction: the starting lenalidomide oral dosing regimen was 10 mg once daily on Days 1 through 21 of each 28 day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
Study NCT03573986 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: [18F]fluoromisonidazole
Description: positron emitting radiopharmaceutical that has been studied in vivo in humans for measurement of regional hypoxia in a number of tumor types with positron emission tomography (PET/CT)
Study NCT03573986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (Avastin, Genentech/Roche) is a humanized monoclonal antibody that binds to VEGF preventing its interaction with VEGFRs resulting in suppression of VEGF signaling.
Study NCT00405756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Double-blind Induction: the starting melphalan oral dosing regimen in all 3 treatment arms was 0.18 mg/kg daily on Days 1 through 4 of each 28-day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
Study NCT00405756 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Melphalan
Description: Double-blind Induction: the starting melphalan oral dosing regimen in all 3 treatment arms was 0.18 mg/kg daily on Days 1 through 4 of each 28-day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
Study NCT00405756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Double-blind induction: the starting prednisone oral dosing regimen in all 3 treatment arms was 2 mg/kg daily on Days 1 through 4 of each 28-day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
Study NCT00405756 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone
Description: Double-blind induction: the starting prednisone oral dosing regimen in all 3 treatment arms was 2 mg/kg daily on Days 1 through 4 of each 28-day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
Study NCT00405756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Double-blind induction: low-dose aspirin 75 mg to 100 mg daily for all treatment arms.~Double-blind maintenance: at the investigator's discretion
Study NCT03573986 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: positron emission tomography (PET/CT).
Description: PET-CT Scan 1.) before start of Bevacizumab up to approximately 4 weeks and 2.) within 12-22 days of start of Bevacizumab
Study NCT02372669 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chitosan nerve tube in addition to gold standard therapy
Description: Primary microsurgical repair of traumatic lesion of sensory nerves of the hand with use of an chitosan nerve tube in addition. Clinical Follow-up will be performed after 3,6,12 and 24 months.
Study NCT02372669 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gold standard Primary microsurgical repair
Description: Primary microsurgical repair of traumatic lesion of sensory nerves of the hand. Clinical Follow-up will be performed after 3,6,12 and 24 months.
Study NCT02372669 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gold standard Primary microsurgical repair
Description: Primary microsurgical repair of traumatic lesion of sensory nerves of the hand. Clinical Follow-up will be performed after 3,6,12 and 24 months.
Study NCT04230837 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inmediate abutment height
Description: The placement of the implant was done following the manufacturing protocol and using a surgical guide according to the radiological guide previously used. At this time, the Permanent® abutment of 1 or 3 mm was chosen randomly and was placed at 35 Ncm.
Study NCT03146988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RGB-02 or Neulasta® (pegfilgrastim)
Description: Pre-filled syringe containing 6 mg RGB-02 or Neulasta® in 0.6 mL, administered as subcutaneous injection into the abdominal area
Study NCT03146988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGB-02 or Neulasta® (pegfilgrastim)
Description: Pre-filled syringe containing 6 mg RGB-02 or Neulasta® in 0.6 mL, administered as subcutaneous injection into the abdominal area